Latigo Biotherapeutics (NASDAQ:LTGO) Reaches New 12-Month High – Time to Buy?

Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) shares reached a new 52-week high during trading on Friday . The company traded as high as $22.90 and last traded at $22.39, with a volume of 143831 shares changing hands. The stock had previously closed at $21.40.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Latigo Biotherapeutics to a “hold” rating in a research report on Saturday, August 15th.

Latigo Biotherapeutics Trading Up 4.5%

Insider Transactions at Latigo Biotherapeutics

In other news, major shareholder Foresite Capital Management V, purchased 140,000 shares of Latigo Biotherapeutics stock in a transaction that occurred on Monday, August 10th. The stock was bought at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the transaction, the insider directly owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. The trade was a 7.49% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director James B. Tananbaum bought 140,000 shares of Latigo Biotherapeutics stock in a transaction on Monday, August 10th. The stock was acquired at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the acquisition, the director owned 2,008,024 shares in the company, valued at approximately $36,144,432. This represents a 7.49% increase in their position. The SEC filing for this purchase provides additional information.

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.